ArticleESC heart failure2020
Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial.
Article in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.Clinical journal of the American Society of Nephrology : CJASN · 2023Trial
- Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial-IRON Trial.Journal of the American Heart Association · 2022Trial
- Effect of Iron Deficiency on Right Ventricular Strain in Patients Diagnosed with Acute Heart Failure.Journal of clinical medicine · 2025Article
- The Impact of Iron Deficiency on Disease Severity and Myocardial Function in Cardiac Amyloidosis.American journal of medicine open · 2024Article
- Iron Dyshomeostasis and Mitochondrial Function in the Failing Heart: A Review of the Literature.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Review
- Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications.European heart journal · 2023Article
- Magnetic resonance imaging of organ iron before and after correction of iron deficiency in patients with heart failure.ESC heart failure · 2023Article
- Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?Life (Basel, Switzerland) · 2023Article
- Iron Deficiency in Heart Failure and Pulmonary Hypertension.Current treatment options in cardiovascular medicine · 2022Article
- Why Iron Deficiency in Acute Heart Failure Should Be Treated: A Real-World Clinical Practice Study.Life (Basel, Switzerland) · 2022Article
- Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction.ESC heart failure · 2022Article
- Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology.Journal of clinical medicine · 2021Review
- Iron Deficiency in CKD Without Concomitant Anemia.Kidney international reports · 2021Review
- ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?Journal of clinical medicine · 2021Review
- Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial.ESC heart failure · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 1 country.
Funding
Abstract
aimsThe mechanisms underlying the beneficial effect of ferric carboxymaltose (FCM) in patients with heart failure (HF) and iron deficiency (ID) have not been completely characterized. The Myocardial-IRON trial was a double-blind, randomized trial that evaluated myocardial iron repletion following FCM vs. placebo in 53 patients with HF and ID. In this post hoc analysis, we evaluated whether treatment with FCM was associated with cardiac magnetic resonance changes in left and right ventricular function (LVEF and RVEF, respectively) at different points of systolic dysfunction. METHODS AND
resultsWe included patients from the Myocardial-IRON trial with left and right ventricular systolic dysfunction (LVSD and RVSD, respectively) at enrolment. Linear mixed regression models were used to evaluate changes at 7 and 30 days on LVEF and RVEF at cardiac magnetic resonance. At enrolment, 27 (50.9%) and 38 (71.7%) patients had LVEF < 40% (LVSD
conclusionsIn patients with HF and systolic dysfunction with ID, FCM was associated with short-term improvement in LVEF and, especially, in RVEF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.